No Data
No Data
No Data
No Data
No Data
3D MEDICINES:二零二三年年報
Futu NewsApr 28 06:04 ET · Announcements
3D MEDICINES (01244.HK) granted a total of 12.8029 million share options
Gelonghui, April 5 | 3D MEDICINES (01244.HK) announced that on April 5, 2024, the company had offered to grant a total of 12,802,850 share options under the 2023 share option plan, subject to acceptance by the share option grantor.
Gelonghui FinanceApr 5 10:09 ET
3D MEDICINES: CLARIFICATION ANNOUNCEMENT REGARDING THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Futu NewsApr 3 10:41 ET · Announcements
3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12%
3D Medicines' (HKG:1244) net loss almost halved in 2023 to HK$524.7 million, or HK$2.30 per share, from HK$1.02 billion, or HK$22.52 per share, the previous year, according to an annual report filed T
MT NewswiresMar 29 04:16 ET
3D MEDICINES (01244.HK) Announces Annual Results R&D Expenses Increased by 21.3% Forward-looking Layouts for Peptide Oncology Vaccines and mRNA Oncology Vaccines
Gelonghui announced on March 28 | 3D MEDICINES (01244.HK) that in 2023, all of the company's revenue will come from the sale of commercialized Enveda (Envolimab, subcutaneous PD-L1) to pharmacy operators and distributors directly cooperating with the company. For the year ended December 31, 2023, the company's revenue increased 11.9% from RMB 567.4 million in the same period in 2022 to RMB 634.9 million, reflecting the rapid growth in sales since Enveda went public in 2021. Thanks to the diversified advantages of products, ahead of schedule
Gelonghui FinanceMar 28 00:43 ET
3D MEDICINES: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY
Futu NewsMar 28 00:11 ET · Announcements
No Data
No Data